G6PC3 and Decreased total neutrophil count: Furthermore, our results also hint that the less specific SGLT2-inhibitor remogliflozin [48], versus the commonly used empagliflozin, could be a better gliflozin to be repurposed to treat neutropenia in G6PC3-deficient and GSD1b patients.